Virax Biolabs Group Limited Ordinary Shares (VRAX)

Price$0.14

Favorite Metrics

Price vs S&P 500 (26W)-85.76%

Price vs S&P 500 (4W)-22.95%

Market Capitalization$1.11M

All Metrics

Book Value / Share (Quarterly)$0.81

P/TBV (Annual)0.32x

Indicated Dividend (Annual)$0.00

Cash Flow / Share (Quarterly)$-0.90

Price vs S&P 500 (YTD)-60.79%

Gross Margin (TTM)-1515.05%

Net Profit Margin (TTM)-188748.83%

EPS (TTM)$-1.25

10-Day Avg Trading Volume51.80M

EPS Excl Extra (TTM)$-1.25

Revenue Growth (5Y)-42.42%

EPS (Annual)$-1.62

ROI (Annual)-99.80%

Gross Margin (Annual)-838.39%

Net Profit Margin (5Y Avg)-33013.30%

Cash / Share (Quarterly)$0.51

Revenue Growth QoQ (YoY)-67.47%

ROA (Last FY)-94.31%

Revenue Growth TTM (YoY)-96.48%

EBITD / Share (TTM)$-1.20

Operating Margin (TTM)-196303.34%

Cash Flow / Share (Annual)$-1.19

P/B Ratio0.21x

P/B Ratio (Quarterly)0.75x

Net Income / Employee (Annual)$-0

EV / Revenue (TTM)-566.79x

Net Interest Coverage (TTM)-105.63x

ROA (TTM)-92.96%

EPS Incl Extra (Annual)$-1.62

Current Ratio (Annual)7.27x

Quick Ratio (Quarterly)9.63x

3-Month Avg Trading Volume8.80M

52-Week Price Return-85.45%

Revenue / Employee (TTM)$0

Tangible BV / Share (Quarterly)$2.09

P/S Ratio (Annual)175.79x

Asset Turnover (Annual)0.00x

52-Week High$1.20

Operating Margin (5Y Avg)-33933.65%

EPS Excl Extra (Annual)$-1.62

26-Week Price Return-77.02%

Quick Ratio (Annual)6.33x

13-Week Price Return-55.01%

Total Debt / Equity (Annual)0.07x

Current Ratio (Quarterly)11.35x

Enterprise Value$-1.695

Revenue / Share Growth (5Y)-28.02%

Asset Turnover (TTM)0.00x

Revenue / Employee (Annual)$0

Inventory Turnover (Annual)0.77x

Pretax Margin (Annual)-98007.74%

Cash / Share (Annual)$0.97

3-Month Return Std Dev171.01%

Gross Margin (5Y Avg)-156.08%

Net Income / Employee (TTM)$-0

ROE (Last FY)-106.41%

Net Interest Coverage (Annual)-92.23x

EPS Basic Excl Extra (Annual)$-1.62

Receivables Turnover (TTM)1.94x

Total Debt / Equity (Quarterly)0.10x

EPS Incl Extra (TTM)$-1.25

ROI (TTM)-94.67%

P/S Ratio (TTM)372.16x

Pretax Margin (5Y Avg)-33474.66%

Revenue / Share (Annual)$0.00

Tangible BV / Share (Annual)$2.09

Price vs S&P 500 (52W)-120.54%

Year-to-Date Return-56.65%

5-Day Price Return-9.92%

EPS Normalized (Annual)$-1.62

ROA (5Y Avg)-1063.54%

Net Profit Margin (Annual)-95754.34%

Month-to-Date Return-31.83%

EBITD / Share (Annual)$-1.56

Operating Margin (Annual)-97360.19%

EPS Basic Excl Extra (TTM)$-1.25

P/TBV (Quarterly)0.32x

P/B Ratio (Annual)0.87x

Inventory Turnover (TTM)0.54x

Pretax Margin (TTM)-198245.48%

Book Value / Share (Annual)$1.31

Price vs S&P 500 (13W)-57.88%

Beta1.28x

Revenue / Share (TTM)$0.00

ROE (TTM)-102.54%

52-Week Low$0.10

Analyst Recommendations

Feb 2026

Mar 2026

Apr 2026

4.14

Industry Peers — In Vitro Diagnostics(17)

Symbol	P/S Ratio (TTM)	Revenue Growth TTM (YoY)	Gross Margin (TTM)	EPS Growth (5Y)	Price
VRAXVirax Biolabs Group Limited Ordinary Shares	372.16x	-96.48%	-1515.05%	—	$0.14
IDXXIdexx Laboratories Inc	10.72x	10.42%	61.80%	14.28%	$583.06
LNTHLantheus Holdings, Inc	3.55x	0.50%	61.10%	40.71%	$83.97
NNNNAnbio Biotechnology Class A Ordinary Shares	295.25x	-5.72%	89.00%	—	$26.98
CLDXCelldex Therapeutics, Inc	1753.49x	-77.98%	17.65%	—	$34.38
NEOGNeogen Corp	2.39x	-3.91%	45.20%	—	$9.63
NTLAIntellia Therapeutics, Inc	26.55x	16.92%	—	—	$15.21
QDELQuidelOrtho Corporation Common Stock	0.32x	-1.89%	46.67%	—	$12.89
MYGNMyriad Genetics Inc	0.59x	-1.56%	69.93%	—	$5.14
ACHVAchieve Life Sciences, Inc.	12.70x	-89.25%	—	—	$4.25
TKNOAlpha Teknova, Inc. Common Stock	3.87x	7.35%	33.17%	—	$2.91

About

Virax Biolabs is a biotechnology company specializing in immune response detection and viral disease diagnostics. The company offers research-use-only assays and immunology services through its ViraxImmune platform and ImmuneSelect portfolio. It is developing T cell-based diagnostic tests targeting post-acute infection syndromes, including Long COVID and other immune dysregulation-related conditions.